Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)
Anika Therapeutics (ANIK) posted quarterly Liabilities from Discontinued Operations of 4122000.0 for Q4 2024, down 61.83% year-over-year from 10799000.0 in Q1 2024, and down 61.83% quarter-over-quarter from 10799000.0 in Q4 2023.
Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Anika Therapeutics (ANIK) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 4122000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Liabilities from Discontinued Operations fell 61.83% year-over-year to 4122000.0; the TTM figure through Dec 2024 stood at 4122000.0 (down 61.83% YoY), while the FY2024 annual figure was 4122000.0, down 61.83% from the prior year.
- Liabilities from Discontinued Operations declined to 4122000.0 in Q4 2024 per ANIK's latest filing, from 10799000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 10799000.0 in Q4 2023 and bottomed at 4122000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | 10.80 Mn |
| Dec 31, 2023 | 10.80 Mn |